Compounds > n(1)-ethyl-n-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine
Page last updated: 2024-12-07

n(1)-ethyl-n-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(1)-ethyl-N-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine: an inhibitor of spermidine-spermine-N(1)-acetyltransferase & antitumor agent against cultured human lung cancer cells; structure given in first source; RN refers to tetrahydrobromide compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127816
CHEMBL ID96761
MeSH IDM0222422

Synonyms (9)

Synonym
CHEMBL96761
cpenspm
nncmdu
n(1)-ethyl-n-(11)-((cyclopropyl)methyl)-4,8-diazaundecane-1,11-diamine
1,3-propanediamine, n-(3-((cyclopropylmethyl)amino)propyl)-n'-(3-(ethylamino)propyl)-, tetrahydrobromide
n-(3-((cyclopropylmethyl)amino)propyl)-n'-(3-(ethylamino)propyl)-1,3-propanediamine tetrahydrobromide
151915-04-7
DTXSID70164906
n'-[3-[3-(cyclopropylmethylamino)propylamino]propyl]-n-ethylpropane-1,3-diamine;tetrahydrobromide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" CPEN-spm, on the other hand, exhibited no toxic effects over the short-term (24 h) exposure period."( Cytotoxicity of novel unsymmetrically substituted inhibitors of polyamine biosynthesis in human cancer cells.
Lindsay, GS; Nairn, LM; Wallace, HM; Woster, PM, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID200622Tested for induction of SSAT activity in H82 SCLC cells following treatment with 10 uM of the BESpm1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine-N1-acetyltransferase (SSAT) and as potential antitumor agents.
AID99978Tested for induction of SSAT activity in H157 LCLC cells following treatment with 10 uM of the BESpm1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine-N1-acetyltransferase (SSAT) and as potential antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (57.14)18.2507
2000's5 (35.71)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
putrescine
[no description available]		2.6930alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		2.420polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		4.4970polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		210nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
n(1),n(11)-diethylnorspermine
N(1),N(11)-diethylnorspermine: structure given in first source		4.4970
cupric chloride
cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.		1.9910copper molecular entity;
inorganic chloride		EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		210taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		210beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.0210actinomycinmutagen
mdl 72527
MDL 72527: RN given refers to di-HCl; RN for parent cpd not available 6/85; polyamine oxidase inhibitor		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Lung
[description not available]		02.940
Lung Neoplasms
Tumors or cancer of the LUNG.		02.940
Breast Cancer
[description not available]		03.8440
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.8440
Hormone-Dependent Neoplasms
[description not available]		03.3120
Carcinoma, Non-Small Cell Lung
[description not available]		02.6830
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.6830
Cancer of Prostate
[description not available]		0210
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		0210
Adenocarcinoma, Basal Cell
[description not available]		02.9110
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.9110